{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:49:09Z","timestamp":1762177749834,"version":"3.41.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jfo.2025.104544","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:28:41Z","timestamp":1746725321000},"page":"104544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study"],"prefix":"10.1016","volume":"48","author":[{"given":"L.","family":"B\u00e9al","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lamiaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Guerrien-Sevrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lasek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Modiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-7092","authenticated-orcid":false,"given":"T.H.C.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2025.104544_bib0185","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2025.104544_bib0190","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2025.104544_bib0195","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"De Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0205","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2013clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jfo.2025.104544_bib0210","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2025.104544_bib0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1203475420929920","article-title":"Incidence of conjunctivitis and other ocular surface disorders in patients with long-term dupilumab use","volume":"24","author":"Jo","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jfo.2025.104544_bib0220","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2025.104544_bib0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0181-5512(07)89557-X","article-title":"M\u00e9thodes d\u2019\u00e9valuation de la surface oculaire dans les syndromes secs","volume":"30","author":"Labb\u00e9","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2025.104544_bib0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1542-0124(12)70086-1","article-title":"Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2025.104544_bib0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1755-3768.1992.tb08579.x","article-title":"A classification for dry eyes following comparison of tear thinning time with Schirmer tear test","volume":"70","author":"Farrell","year":"1992","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.jfo.2025.104544_bib0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00347-017-0473-3","article-title":"Ocular involvement in atopic dermatitis: clinical aspects and therapy","volume":"114","author":"Maier","year":"2017","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.jfo.2025.104544_bib0245","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u00a0\u2013\u00a0international eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2025.104544_bib0250","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jfo.2021.12.007","article-title":"Dupilumab-related blepharoconjunctivitis: recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: which management approach?","volume":"45","author":"Doan","year":"2022","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2025.104544_bib0255","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients withatopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life french multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0265","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.jfo.2025.104544_bib0275","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0280","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2025.104544_bib0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jfo.2025.104544_bib0290","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0300","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09546634.2019.1682503","article-title":"Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis","volume":"32","author":"Fargnoli","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jfo.2025.104544_bib0305","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1111\/jdv.16219","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life italian tertiary centre experience","volume":"34","author":"Ribero","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2025.104544_bib0310","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.18932","article-title":"Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat","year":"2023","journal-title":"Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2025.104544_bib0315","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/jdv.15118","article-title":"Dupilumab: short-term effectiveness and security in real clinical practice\u00a0\u2013\u00a0a retrospective multicentric study","volume":"33","author":"Ruiz-Villaverde","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2025.104544_bib0320","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.18041","article-title":"Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series","volume":"181","author":"Armario-Hita","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfo.2025.104544_bib0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-Associated Mucin Deficiency (DAMD)","volume":"9","author":"Barnett","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.jfo.2025.104544_bib0330","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1080\/09273948.2018.1511811","article-title":"Immunopathological features of severe chronic atopic keratoconjunctivitis and effects of topical cyclosporine treatment","volume":"27","author":"Utine","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2025.104544_bib0335","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2025.104544_bib0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.jfo.2025.104544_bib0345","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jfo.2025.104544_bib0350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report","volume":"5","author":"Zirwas","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jfo.2025.104544_bib0355","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2025.104544_bib0360","first-page":"390","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit Amst Neth"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551225001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551225001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T21:57:18Z","timestamp":1748642238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551225001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0181551225001263"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2025.104544","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2025.104544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104544"}}